Skip to content
10-K

Annual Report

Dogwood Therapeutics, Inc. DWTX

0001104659-26-031061

← back to feed
Filed
Mar 18, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2025 · Mar 10, 2026 33.4M sh
Shares Diluted FY 2025 · Dec 31, 2025 4.98M sh
Shares Diluted FY 2025 · Dec 31, 2024 1.03M sh
Operating Cash Flow FY 2025 · Dec 31, 2025 −$15.62M
Operating Cash Flow FY 2025 · Dec 31, 2024 −$8.79M
Cash And Equivalents FY 2025 · Dec 31, 2025 $6.52M
Cash And Equivalents FY 2025 · Dec 31, 2024 $14.85M
Stockholders Equity FY 2025 · Dec 31, 2025 $74.9M
Stockholders Equity FY 2025 · Dec 31, 2024 −$10.12M
Current Liabilities FY 2025 · Dec 31, 2025 $3.06M
Current Liabilities FY 2025 · Dec 31, 2024 $3.18M
Total Liabilities FY 2025 · Dec 31, 2025 $15.27M
Total Liabilities FY 2025 · Dec 31, 2024 $30.03M
Current Assets FY 2025 · Dec 31, 2025 $8.43M
Current Assets FY 2025 · Dec 31, 2024 $16.54M
Total Assets FY 2025 · Dec 31, 2025 $90.17M
Total Assets FY 2025 · Dec 31, 2024 $94.31M
Eps Diluted FY 2025 · Dec 31, 2025 −$7.13
Eps Diluted FY 2025 · Dec 31, 2024 −$12.52
Eps Basic FY 2025 · Dec 31, 2025 −$7.13
Eps Basic FY 2025 · Dec 31, 2024 −$12.52
Sga Expense FY 2025 · Dec 31, 2025 $6.1M
Sga Expense FY 2025 · Dec 31, 2024 $8.7M
Rd Expense FY 2025 · Dec 31, 2025 $21.87M
Rd Expense FY 2025 · Dec 31, 2024 $3.53M
Net Income FY 2025 · Dec 31, 2025 −$34.26M
Net Income FY 2025 · Dec 31, 2024 −$12.35M
Operating Income FY 2025 · Dec 31, 2025 −$27.97M
Operating Income FY 2025 · Dec 31, 2024 −$12.23M